Shattuck Labs, Inc.
corporate_fare Company Profile
Shattuck Labs, Inc. (NASDAQ:STTK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for STTK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for STTK spans 8-K, 10-Q, SCHEDULE 13D/A, 4.
Recent high-impact activity:
- Shattuck Q3 Loss Widens to $25.2M as SL-325 Phase 2b Crohn's Trial Begins
- Shattuck Q3 Loss Widens to $25.2M as R&D Spending Nearly Triples
- Shattuck Labs Expands SL-325 Into Phase 2 Hidradenitis Suppurativa Trial, Adds Clinical Development SVP
- Shattuck Labs Q2 2026: Cash Runway into 2029, Phase 2b Crohn's Trial Set for Q3 Launch
- Shattuck Labs Q2 2026: Cash Runway Extended into 2029, Phase 2b Crohn's Trial to Start in Q3
Financial Snapshot
Short Interest & Short Volume
11.97 days to coverFINRA reported short interest of 10,745,702 shares in STTK as of the October 30, 2026 settlement, a 2.9% increase from the prior period — about 12.0 days to cover at its recent average daily volume. On November 20, 2026, 53.9% of STTK volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for STTK, detected from its recent SEC filings · based on capital-structure filings through 2026-06-11.
Public Offering Finalized · Pricing Details
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →